Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17244781 | 0.82 | CA1 (0.47) | CTSKMAPTMEN1KMT2ANPSR1 | |
| SCHEMBL16364941 | 0.80 | CTSK (0.50) | CTSKMAPTMEN1KMT2ACTSL | |
| SCHEMBL699601 | 0.78 | MAPT (0.61) | CTSKMAPTCTSLCTSBPOLB | |
| SCHEMBL12247705 | 0.78 | MAPT (0.61) | CTSKMAPTCTSLCTSBPOLB | |
| SCHEMBL5276867 | 0.78 | CTSK (0.48) | CTSKCTSLCTSB | |
| SCHEMBL906631 | 0.78 | CTSK (0.48) | CTSKCTSLCTSB | |
| SCHEMBL3498473 | 0.77 | CTSK (0.60) | CTSKMEN1KMT2AGAATDP1 | |
| SCHEMBL3818710 | 0.77 | CTSK (0.60) | CTSKMEN1KMT2AGAATDP1 | |
| SCHEMBL18236363 | 0.77 | CTSK (0.49) | CTSKMAPTMEN1KMT2AGAA | |
| SCHEMBL4821212 | 0.76 | MAPT (0.66) | CTSKMAPTCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382202-B2 | Precursor for labeling therapeutic agent for liver cancer and method for manufacturing the same | Atomic Energy Council—Institute of Nuclear Energy Research (TW) | 2016-07-05 | — | — | US | disclosed |
| US-20150322005-A1 | PRECURSOR FOR LABELING THERAPEUTIC AGENT FOR LIVER CANCER AND METHOD FOR MANUFACTURING THE SAME | ATOMIC ENERGY COUNCIL-INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322005-A1 | PRECURSOR FOR LABELING THERAPEUTIC AGENT FOR LIVER CANCER AND METHOD FOR MANUFACTURING THE SAME | FABP1, LIPC, HCCS | CTSK 1910/4885MAPT 4151/4885MEN1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.